Jackson Hole Capital Partners LLC Acquires New Shares in Kenvue Inc. (NYSE:KVUE)

Jackson Hole Capital Partners LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 22,360 shares of the company’s stock, valued at approximately $481,000.

Several other large investors have also bought and sold shares of KVUE. Vanguard Group Inc. acquired a new stake in shares of Kenvue during the third quarter valued at about $2,944,816,000. FMR LLC raised its position in shares of Kenvue by 572.1% during the third quarter. FMR LLC now owns 89,182,980 shares of the company’s stock worth $1,790,794,000 after acquiring an additional 75,913,107 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Kenvue by 576.1% during the third quarter. Wellington Management Group LLP now owns 71,686,830 shares of the company’s stock worth $1,439,472,000 after acquiring an additional 61,084,123 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Kenvue by 227.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 61,091,189 shares of the company’s stock worth $1,226,711,000 after acquiring an additional 42,449,470 shares during the last quarter. Finally, Morgan Stanley raised its position in shares of Kenvue by 4,057.4% during the third quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock worth $625,745,000 after acquiring an additional 30,413,040 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of KVUE stock traded down $0.16 during trading on Friday, hitting $18.86. The company’s stock had a trading volume of 15,451,237 shares, compared to its average volume of 16,691,828. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The business has a fifty day moving average of $19.84 and a 200-day moving average of $20.14. Kenvue Inc. has a 52 week low of $17.82 and a 52 week high of $27.80.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. On average, research analysts expect that Kenvue Inc. will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th will be given a dividend of $0.20 per share. The ex-dividend date is Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a yield of 4.24%.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on KVUE. The Goldman Sachs Group began coverage on Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price objective for the company. Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. Sanford C. Bernstein initiated coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price for the company. JPMorgan Chase & Co. lowered their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. Finally, William Blair initiated coverage on Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.